Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
09 7월 2024 - 5:30AM
AMF Regulated
InformationMontrouge, France, July 8, 2024
Half-Year Report on the DBV Technologies
Liquidity Contract with ODDO BHF
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today issued the Half-Year report on its
liquidity contract with ODDO BHF.
Under the liquidity contract between DBV
Technologies and ODDO BHF, the following assets appeared on the
liquidity account as of June 30, 2024:
- 303,744 DBV Technologies
shares,
- € 62,415.60
When the liquidity contract with ODDO BHF was
implemented, as of July 1, 2018, the following assets were included
in the liquidity account:
- 41,159 DBV Technologies
shares,
- € 432,367.25.
Over the period from January 1, 2024, to June
30, 2024, the following transactions were executed:
- 912 buy transactions,
- 694 sales transactions.
Over this same period, the volumes traded
represented:
- 299,986 shares and € 397,966 on
purchases,
- 219,230 shares and € 310,114 on
sales.
About DBV Technologies
DBV Technologies is a clinical-stage
biopharmaceutical company developing treatment options for food
allergies and other immunologic conditions with significant unmet
medical need. DBV is currently focused on investigating the use of
its proprietary technology platform, Viaskin™, to address food
allergies, which are caused by a hypersensitive immune reaction and
characterized by a range of symptoms varying in severity from mild
to life-threatening anaphylaxis. Millions of people live with food
allergies, including young children. Through epicutaneous
immunotherapy (EPIT™), the Viaskin platform is designed to
introduce microgram amounts of a biologically active compound to
the immune system through intact skin. EPIT is a new class of
non-invasive treatment that seeks to modify an individual’s
underlying allergy by re-educating the immune system to become
desensitized to allergen by leveraging the skin’s immune tolerizing
properties. DBV is committed to transforming the care of food
allergic people. The Company’s food allergy programs include
ongoing clinical trials of Viaskin Peanut in peanut allergic
toddlers (1 through 3 years of age) and children (4 through 7 years
of age).
DBV Technologies is headquartered in Châtillon,
France, with North American operations in Warren, NJ. The Company’s
ordinary shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345) and the Company’s ADSs (each
representing one ordinary share) are traded on the Nasdaq Stock
Market (Ticker: DBVT).
For more information, please visit
www.dbv-technologies.com and engage with us on X (formerly Twitter)
and LinkedIn.
Viaskin and EPIT are trademarks of DBV
Technologies.
Investor Contact Katie Matthews
DBV Technologies katie.matthews@dbv-technologies.com
Media Contact Angela Marcucci
DBV Technologies angela.marcucci@dbv-technologies.com
DBV Technologies (EU:DBV)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 12월(12) 2024
DBV Technologies (EU:DBV)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
